Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "Smart Watches Market, By Price Range, By Operating System, By Region- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
This report presents a comprehensive analysis of the global hemorrhagic shock treatment market, projecting significant growth from its current valuation of $206.3 million in 2023 to an estimated $279.5 million by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 4.4%.
Understanding Hemorrhagic Shock and Controlled Hemorrhagic Shock (CHS)
Hemorrhagic shock, a critical medical condition characterized by inadequate oxygen and nutrient delivery to cells due to tissue perfusion impairment, often results from traumatic injuries. Uncontrolled bleeding can lead to hemorrhagic shock, necessitating immediate intervention. The primary treatment approach involves promptly controlling the source of bleeding and replenishing lost fluids.
Controlled Hemorrhagic Shock (CHS) involves the methodical replacement of fluids to restore hemodynamic parameters once bleeding has ceased. This treatment approach is essential, especially in scenarios involving gynecological and obstetric situations. The body's response to reduced blood volume triggers sympathetic compensation, marked by increased heart rate, peripheral vasoconstriction, and heightened myocardial contractility, which subsequently elevates the oxygen demands on the heart muscle.
Dynamic Market Dynamics and Innovative Solutions
The understanding of hemorrhagic shock's pathophysiology is evolving, leading to a broader range of trauma treatment strategies beyond simple massive transfusions. Innovative solutions are emerging, such as VirTech's development of a hemoglobin-based solution with blood-like oxygen carrying capacity. The US Department of Defense's investment of $13 million to support its clinical research phase underscores the potential of this solution. The overarching goal is to prevent hemorrhagic shock in trauma patients and enhance organ survival for transplantation, significantly impacting the treatment landscape.
Market Segmentation:
- Global Hemorrhagic Shock Treatment Market, By Drug Type:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
- Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
- Global Hemorrhagic Shock Treatment Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- North America
Company Profiles:
- Biomedica Management Corporation
- NuvOxPharma LLC
- Leading BioSciences, Inc
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Johnson & Johnson Services Inc
- AstraZeneca
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- ZydusCadila
- Amneal Pharmaceuticals LLC
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $28.72 Billion |
| Forecasted Market Value (USD) by 2030 | $57.09 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/4gcg5y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
